Alligator Bioscience AB (OSTO:ATORX) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:ATORX Alligator Bioscience AB OSTO:ATORX
39 GF Score
Price kr0.18
GF Value kr0.01
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Alligator Bioscience AB FFO?

FFO (Funds from operations) only applies to REITs.

OSTO:ATORX
39GF Score
Alligator Bioscience AB OSTO:ATORX
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Alligator Bioscience AB (OSTO:ATORX) Overvalued in 2026?

Based on GuruFocus' analysis, Alligator Bioscience AB stock appears to be overvalued. The current stock price of kr0.18 is trading 1676% above its estimated GF Value™ of kr0.01. GuruFocus considers Alligator Bioscience AB to be Significantly Overvalued.

Key valuation signals for OSTO:ATORX:

  • FFO:
  • GF Value™: kr0.01 vs. price of kr0.18 (1676% above fair value)
  • GF Score™: 39/100 with 7 warning signs

No single metric tells the full story. See the OSTO:ATORX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Alligator Bioscience AB Business Description

Other Exchanges 0RK9:UK7AL0:Germany
Address Scheeletorget 1, Medicon Village, Lund, SWE, 223 81
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. The company's main drug candidate, mitazalimab, is currently under development as a therapy for metastatic pancreatic cancer patients. Its development pipeline also comprises: ATOR-4066, a bispecific antibody targeting CD40, as well as CEACAM5 (carcinoembryonic antigen 5), a protein found in certain tumors; and certain externally developed programs like HLX22 and ALG.APV-527. Geographically, the company generates maximum revenue from Belgium (mainly through out-licensing), and also has its presence in Sweden and Finland.
39GF Score

Get the complete analysis for OSTO:ATORX

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.18
Price
kr0.01
GF Value